# Amarin Corp Plc\uk (AMRN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/amarin-corp-plc-uk/ JSON: https://steadybase.io/company/amarin-corp-plc-uk.json Checked Nov 21, 2026. Latest filing read: Oct 28, 2026.

## Company

- Legal name: AMARIN CORP PLC\UK
- Ticker: AMRN (Nasdaq)
- SEC CIK: 0000897448
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Dublin 2
- Fiscal year ends: December 31
- SEC filer category: Accelerated filer
- Website: amarincorp.com
- LinkedIn: https://www.linkedin.com/company/amarin-corporation
- Next earnings date: Jan 20, 2027

## Key facts

- Revenue: $213.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/0001193125-26-085818-index.html
- Operating income: -$50.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/0001193125-26-085818-index.html
- Net income: -$38.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/0001193125-26-085818-index.html
- SG&A: $115.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/0001193125-26-085818-index.html
- Shares outstanding: 380,694 as of Feb 20, 2013 (10-K filed Feb 28, 2013). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312513084191/0001193125-13-084191-index.html
- Auditor: Ernst & Young LLP, Iselin, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $213.6M | -$50.2M | -$38.8M | $115.0M |
| Dec 31, 2024 | $228.6M | -$91.8M | -$82.2M | $152.3M |
| Dec 31, 2023 | $306.9M | -$67.6M | -$59.1M | $199.9M |
| Dec 31, 2022 | $369.2M | -$105.9M | -$105.8M | $304.4M |
| Dec 31, 2021 | $583.2M | $10.5M | $7.7M | $408.3M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/amarin-corp-plc-uk.json

## Officers and directors

- Aaron Berg, President & Chief Executive Officer. LinkedIn: https://linkedin.com/in/aaron-berg-7b13033. Source: 8-K filed Oct 28, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-ex99_1.htm
- Peter Fishman, Amarin’s Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/peter-l-fishman. Source: 8-K filed Oct 28, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-ex99_1.htm
- Peter L. Fishman, SVP, CFO. Source: Form 4 filed Aug 3, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526330669/0001193125-26-330669-index.htm
- David Paul Keenan, EVP, Chief Operating Officer. Source: Form 4 filed Jul 15, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526304912/0001193125-26-304912-index.htm
- Jonathan Provoost, EVP, Chief Legal Officer. LinkedIn: https://linkedin.com/in/jonathan-provoost-5b02343. Source: Form 4 filed Jul 15, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526304910/0001193125-26-304910-index.htm
- Steven B. Ketchum, EVP, Chief Scientific Officer. Source: Form 4 filed Jul 15, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526304911/0001193125-26-304911-index.htm
- Diane E. Sullivan, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Keith L. Horn, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Louis Sterling III., Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Michael Torok, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Odysseas Kostas, M.D., Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Oliver O'Connor, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Patrice Bonfiglio, Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Paul Cohen, M.D., Director. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- Jonathan N. Provoost, Executive Vice President, Chief Legal & Compliance Officer and Secretary. Source: DEF 14A filed Apr 10, 2026, https://www.sec.gov/Archives/edgar/data/897448/000119312526151417/amrn-20260410.htm

## Recent 8-K events

- Nov 18, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526467256/amrn-20261116.htm
- Oct 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-20261028.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526323841/amrn-20260729.htm
- May 15, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526224771/amrn-20260513.htm
- Apr 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/amrn-20260429.htm
- Mar 27, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526129334/amrn-20260325.htm
- Feb 25, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526068511/amrn-20260225.htm
- Jan 8, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/amrn-20260108.htm
- Oct 29, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312525254620/amrn-20251029.htm
- Oct 22, 2025: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/897448/000119312525246973/amrn-20251017.htm

## What management said

- "Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value" Aaron Berg, President & Chief Executive Officer (8-K filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-ex99_1.htm
- "We reported our first profitable quarter in over two years, reflecting our lower expense base and the absence of charges following the completion of our previously announced $70 million cost savings initiatives. We generated positive free cash flow for the fourth consecutive quarter. Our cash balance now exceeds $323 million and our balance sheet remains debt-free" Peter Fishman, Amarin’s Chief Financial Officer (8-K filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-ex99_1.htm

## Latest filings

- 8-K filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-20261028.htm
- 10-K filed Mar 2, 2026: https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm
- 10-Q filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/897448/000119312526435082/amrn-20260930.htm
- DEF 14A filed Apr 10, 2026: https://www.sec.gov/Archives/edgar/data/897448/000119312526151417/amrn-20260410.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

